Cytokinetics (CYTK) Cost of Revenue (2026)

Cytokinetics (CYTK) posted quarterly Cost of Revenue of $160000.0 for Q1 2026.

Cytokinetics (CYTK) Cost of Revenue (2026) Analysis & Trends

Cytokinetics (CYTK) has reported Cost of Revenue for 1 consecutive years, with $160000.0 the latest figure, recorded in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	489.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	360.70 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	145.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	174.53 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.18 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	298.26 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	67.21 Mn
10	Cytokinetics	10.31 Bn	9.14 Bn	25.89 Mn	2.73 Mn

Download Data